Revance Therapeutics, Inc. provided revenue guidance for the year 2024. The company expects 2024 total product revenue, which includes sales of DAXXIFY and the RHA Collection, to be at least $280 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.02 USD | -4.43% | -9.04% | -65.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-65.64% | 315M | |
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B | |
-6.32% | 8.35B |
- Stock Market
- Equities
- RVNC Stock
- News Revance Therapeutics, Inc.
- Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024